Toleranzia
0.65
SEK
+9.8 %
TOL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+9.8%
+16.07%
+9.43%
+25.48%
+20.82%
+0.93%
-43.48%
-76.34%
-90.14%
Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.
Read moreMarket cap
176.13M SEK
Turnover
86.83K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
21.2
2025
Annual report '24
6.5
2025
Interim report Q1'25
5.6
2025
General meeting '25
ShowingAll content types
Toleranzia AB appoints SKMG as new Certified Adviser
Toleranzia AB publishes the Nomination Committee
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools